LIFECORE BIOMEDICAL, INC. Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount
LIFECORE BIOMEDICAL, INC. (LFCR) reported Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount of -$3.70 million for the 7-month period ending 2025-12-31, per its 10-KT filed 2026-03-16.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate · last filed 2026-03-16
- LIFECORE BIOMEDICAL, INC. effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2025 was -$8.12M, a 506.51% decline from fiscal 2024.
- LIFECORE BIOMEDICAL, INC. effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2024 was $2.00M.
- LIFECORE BIOMEDICAL, INC. effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2023 was -$13.93M.
- LIFECORE BIOMEDICAL, INC. effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2022 was -$4.34M.
| Period end | Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount 7 month | Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount 12 month | Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount 12 month as first filed |
|---|---|---|---|
| 2025-12-31 | -$3.70M 10-KT · filed 2026-03-16 | ||
| 2025-05-25 | -$8.12M 10-KT · filed 2026-03-16 | ||
| 2024-05-26 | $2.00M 10-KT · filed 2026-03-16 | $2.00M 10-K · filed 2024-08-26 | |
| 2023-05-28 | -$13.93M 10-K · filed 2024-08-26 | ||
| 2022-05-29 | -$4.34M 10-K · filed 2024-08-26 | -$10.90M 10-K · filed 2022-09-14 | |
| 2021-05-30 | -$6.26M 10-K · filed 2024-03-20 | -$8.50M 10-K · filed 2021-07-29 | |
| 2020-05-31 | -$6.43M 10-K/A · filed 2023-03-16 | -$10.77M 10-K · filed 2020-08-14 | |
| 2019-05-26 | $764.00K 10-K · filed 2021-07-29 | ||
| 2018-05-27 | $4.78M 10-K · filed 2020-08-14 | ||
| 2017-05-28 | $4.92M 10-K · filed 2019-08-01 | $5.22M 10-K · filed 2017-08-11 | |
| 2016-05-29 | -$6.96M 10-K · filed 2018-08-09 | -$6.67M 10-K · filed 2016-08-01 | |
| 2015-05-31 | $7.45M 10-K/A · filed 2018-03-15 | ||
| 2014-05-25 | $10.40M 10-K · filed 2016-08-01 | ||
| 2013-05-26 | $11.21M 10-K · filed 2015-07-31 | ||
| 2012-05-27 | $6.96M 10-K · filed 2014-08-01 | ||
| 2011-05-29 | $2.83M 10-K · filed 2013-08-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B |